1.Quick detail:

CAS:82640-04-8

Melting point: 250-253°C

Chemical Properties:Light-Yellow Solid

Purity: 99% Molecular Formula: C28H29NO4S

Molecular Weight: 475.5992

Specification: USP

Uses: For osteoporosis prevention of postmenopausal women

Packing: 1kg/aluminum foil bag

Min. Order quantity: 10g

Payment: Western Union, Moneygram

Shipment: EMS, DHL, FedEx

Delivery: Safe & timely, around 7days after payment.

2. Raloxifene hydrochloride Description:

Raloxifene hydrochloride is a second-generation Selective Estrogen Receptor Modulator (SERM) of the benzothiophene family. This drug is similar in effect to tamoxifen, exhibiting estrogen receptor antagonist (blocking) properties in some tissues while acting as an estrogen receptor agonist (activator) in others.

The main point of variation between these two agents is their tissue selectivity. While raloxifene hydrochloride is a strong anti-estrogen in breast and uterine tissues, it appears to be estrogenic in bone. This allows it to protect bone density, mimicking the beneficial effects of endogenous estradiol. This is quite different from tamoxifen, which is anti-estrogenic in both breast and bone.

In a role that was novel for an anti-estrogen, raloxifene hydrochloride was approved by the FDA for the prevention and treatment of osteoporosis in post-menopausal women. It is also being investigated for several other potential uses, including the treatment and prevention of cardiovascular disease, breast cancer, gynecomastia, prostate cancer, acromegaly, and uterine cancer.

3. Raloxifene hydrochloride Mechanism of Action:

Evista (raloxifene hydrochloride) is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophene class of compounds. The biological actions of raloxifene are largely mediated through binding to estrogen receptors.

This binding results in activation of estrogenic pathways in some tissues (agonism) and and the blockade of estrogenic pathways in other tissues (antagonism). The agonistic or antagonistic activity of raloxiffene depends on the extent of recruitment of coactivators and corepressors to estrogen receptor (ER) target gene promotors.

Raloxifene appears to act as an estrogen agonist in bone. It decreases bone resorption and bone turnover, increases bone mineral density and decreases fracture incidence.

4. Raloxifene hydrochloride Administration:

Raloxifene hydrochloride is FDA approved for the treatment and prevention of osteoporosis in postmenopausal women, reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis, and reducing the risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

The recommended dose is one 60 mg tablet administered once per day, without regard to meals. When used (off-label) to mitigate the estrogenic side effects of anabolic/androgenic steroid use, male athletes and bodybuilders often take 30 mg to 60 mg per day.